Early Type 1 Diabetes Screening in Community Health Centers: What We Learned

Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing cells in the pancreas. Before symptoms appear, the body produces autoantibodies—proteins that signal this attack is underway. Identifying these autoantibodies early, before a child becomes ill, offers a window for intervention and allows families time to prepare.

Most Type 1 diabetes screening research has focused on privileged populations with good access to healthcare. This study aimed to bring early detection into a federally qualified health center (FQHC)—a primary care setting serving economically and culturally diverse urban families—to reach communities that have historically been left out of these efforts.

Researchers embedded the Autoimmunity Screening for Kids (ASK) program into well-child visits for children aged 12 to 24 months at an urban FQHC. Over 8 months, the team trained all 13 clinic staff members, redesigned workflows to include screening, and created culturally tailored educational materials to help families understand the purpose of the test.

Of 359 eligible children, caregivers of 86 (24%) consented to participate and had their child's blood drawn for autoantibody testing. The families who participated reflected the clinic population: 77% identified as Hispanic/Latino, and 28% spoke Spanish at home.

One child screened positive for islet autoantibodies (1% of those tested) and was connected to follow-up care. All 13 clinicians completed training and ordered at least one screening test, which showed that staff buy-in was achievable.

However, screening numbers remained below targets and eventually stopped. The research team identified several barriers: limited time during well-child visits, other clinical priorities competing for attention, difficulty completing informed consent conversations within routine appointments, and disruptions caused by research protocol requirements that didn't fit smoothly into daily clinic operations.

Despite these challenges, caregivers who participated expressed strong support for the idea of early Type 1 diabetes identification in their community.

This study demonstrates that autoantibody screening can work in diverse, underserved community health settings—but it also reveals why simply transferring a research program into a busy clinic is not enough. The gap between what works in a research study and what can be sustained in everyday clinical practice is real and significant.

The researchers concluded that embedding T1D screening into routine care is feasible in concept, but sustainability requires structural changes at the clinic and health system level. These might include protected time for screening conversations, streamlined workflows that don't disrupt existing care, and simpler processes that don't rely heavily on research protocols.

The strong support from families—especially from communities historically excluded from T1D research—suggests there is real demand for early detection in diverse populations. The next steps involve figuring out how to meet that demand in ways that work within the real constraints of community health centers.

Source: Academic pediatrics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.